High Net Worth Advisory Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-10,066
Closed -$244K 241
2025
Q2
$244K Sell
10,066
-1,810
-15% -$42.2K 0.06% 200
2025
Q1
$301K Sell
11,876
-1,200
-9% -$31.4K 0.08% 164
2024
Q4
$347K Sell
13,076
-21,886
-63% -$594K 0.1% 158
2024
Q3
$1.01M Buy
34,962
+16,316
+88% +$476K 0.28% 81
2024
Q2
$522K Sell
18,646
-6,355
-25% -$175K 0.16% 113
2024
Q1
$694K Buy
25,001
+600
+2% +$16.6K 0.22% 97
2023
Q4
$703K Sell
24,401
-14,239
-37% -$430K 0.26% 88
2023
Q3
$1.28M Sell
38,640
-1,625
-4% -$57.5K 0.51% 51
2023
Q2
$1.48M Buy
40,265
+2,575
+7% +$100K 0.57% 47
2023
Q1
$1.54M Sell
37,690
-3,101
-8% -$134K 0.63% 45
2022
Q4
$2.09M Sell
40,791
-1,527
-4% -$73.2K 0.81% 24
2022
Q3
$1.85M Sell
42,318
-300
-0.7% -$14.6K 0.79% 27
2022
Q2
$2.23M Buy
42,618
+1,969
+5% +$100K 0.93% 22
2022
Q1
$2.1M Buy
40,649
+2,112
+5% +$110K 0.76% 32
2021
Q4
$2.28M Buy
+38,537
New +$1.91M 0.79% 32

Other funds holding PFE

High Net Worth Advisory Group's PFE Position: Q3 2025 in Review

High Net Worth Advisory Group sold out of Pfizer (PFE) in Q3 2025, closing a stake of 10,066 shares — an estimated $244K sold.

High Net Worth Advisory Group first reported a position in PFE in Q4 2021 and held it in 15 quarters. The position peaked at $2.28M in Q4 2021. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • High Net Worth Advisory Group reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • High Net Worth Advisory Group sold 10,066 Pfizer shares in Q3 2025, an estimated $244K.
  • High Net Worth Advisory Group first reported a position in Pfizer in Q4 2021 and held it in 15 quarters.
  • High Net Worth Advisory Group's Pfizer position peaked at $2.28M in Q4 2021.
  • 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on High Net Worth Advisory Group's 13F filing for Q3 2025, filed 29 Oct 2025.